DarioHealth Corp. (DRIO)
| Market Cap | 57.02M +67.2% |
| Revenue (ttm) | 22.36M -17.3% |
| Net Income | -40.31M |
| EPS | -10.12 |
| Shares Out | 7.30M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4,230 |
| Open | 7.37 |
| Previous Close | 8.13 |
| Day's Range | 7.37 - 8.18 |
| 52-Week Range | 5.94 - 17.74 |
| Beta | 1.09 |
| Analysts | Strong Buy |
| Price Target | 35.00 (+348.14%) |
| Earnings Date | May 13, 2026 |
About DRIO
DarioHealth Corp. operates as a digital health company in the United States and internationally. Its digital therapeutics platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. The company offers Dario Connect, a solution used to create communities around specific health conditions to increase awareness and education; Dario Mind, a behavioral health offering that decreases the sympt... [Read more]
Financial Performance
In 2025, DarioHealth's revenue was $22.36 million, a decrease of -17.31% compared to the previous year's $27.04 million. Losses were -$40.31 million, 34.0% more than in 2024.
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for DRIO stock is "Strong Buy." The 12-month stock price target is $35.0, which is an increase of 348.14% from the latest price.
News
DarioHealth to Report First Quarter 2026 Results on Wednesday, May 13, 2026
Company to host conference call and webcast at 8:30 a.m. Eastern Time NEW YORK, May 4, 2026 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital ...
Dario Demonstrates Improved Workplace Function and Productivity Outcomes Through Digital Behavioral Health Program: Real-World Study Published in JMIR Formative Research
Findings highlight the role of continuous behavioral support in improving focus, productivity and day-to-day functioning – key priorities for employers and health plans Statistically significant impro...
Dario Appoints Veteran Healthcare Executive John R. Palumbo to Board of Directors to Support Accelerated Commercial Scaling
Mr. Palumbo's deep relationships across health systems, payers and healthcare's senior executive community expected to accelerate Dario's commercial partnerships and position the Company to realize it...
DarioHealth trading halted, volatility trading pause
12:50 EDT DarioHealth (DRIO) trading halted, volatility trading pause
One new option listing and ten option delistings on March 23rd
New option listings for March 23rd include Roundhill Top Weeklypay Etf (TOPW). Option delistings effective March 23rd include CALVERT US SELECT EQUITY (CVSE), DarioHealth (DRIO), Enlightify Inc (ENFY)...
DarioHealth price target lowered to $10 from $16 at Stifel
Stifel lowered the firm’s price target on DarioHealth (DRIO) to $10 from $16 and keeps a Buy rating on the shares. The firm continues to model 2025 and 2026 revenue
DarioHealth files $100M mixed securities shelf
17:04 EDT DarioHealth (DRIO) files $100M mixed securities shelf
DarioHealth Earnings Call Transcript: Q4 2025
Record new business wins in 2025 offset a legacy client loss, with Q4 revenue growth and expanding gross margins. Pipeline value surged to $122 million, and cost discipline plus AI efficiencies are expected to drive a 30% reduction in operating loss in 2026, targeting cash flow breakeven by mid-2027.
DarioHealth reports Q4 revenue $5.2M, consensus $5.05M
“2025 was our strongest commercial year on record – 85 new agreements signed and contracted and late stage ARR contracts representing $12.9 million are expected to begin converting to revenue
DarioHealth Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
Fourth quarter 2025 revenues grew sequentially to $5.2 million as compared to $5.0 million in the third quarter of 2025 2025 full-year revenue was $22.4 million, compared to $27.0 million in 2024, due...
DarioHealth to Report Fourth Quarter and Full Year 2025 Results on Thursday, March 19, 2026
Company to host conference call and webcast at 8:30 a.m. Eastern Time NEW YORK, March 11, 2026 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digit...
Dario Demonstrates Clinically Meaningful Blood Glucose Improvements and Personalized Glycemic Trajectories Across 22,000+ Users: Machine Learning Study Findings Published in Frontiers in Digital Health
Findings reinforce that engagement data provide clinical signals directly impacting ROI Analysis further reveals specific frequency of measurements that drive clinical outcomes and bend the cost curve...
Dario Uniquely Positioned to Amplify the Impact of Oral GLP-1 Therapies Through Precision Behavioral Support: 79% of Members Already Using Dario's Weight Management
As oral GLP-1s enter the market with slightly more modest weight and glycemic outcomes than injectable formulations, Dario integrates structured behavioral reinforcement to optimize real-world success...
Dario Surpasses 100 Scientific Studies, Cementing Leadership Among Digital Health's Most Evidence-Based Platforms
Growing body of peer-reviewed publications and rigorously reviewed conference research reinforces Dario's position as trusted partner for organizations seeking to reduce cost, improve outcomes and sim...
Dario Launches DarioIQ™ AI Integration in Dario Health App with Direct-to-Consumer First Version for Hypertension Members
First in-market activation of Dario's GenAI roadmap lays clinical and technical foundation for a seamless, conversational AI experience across the entire Dario platform DarioIQ™ reflects years of inno...
DarioHealth’s digital health platform shows blood pressure improvements
DarioHealth (DRIO) announced publication of a new peer-reviewed study in JMIR Cardio demonstrating that data-driven nudges delivered via Dario’s digital health platform are associated with significant...
Dario's Data-Driven Digital Health Platform Delivers Significant and Sustainable Improvements in Blood Pressure: Findings Published in JMIR Cardio
Peer-reviewed JMIR Cardio study demonstrates real-world clinical impact of data-driven digital nudges on hypertension outcomes Data-driven engagement translates to lower health risks and downstream co...
DarioHealth announces 79 new accounts signed year-to-date
DarioHealth (DRIO) announced that it has secured 34 new employer clients in the past two weeks, reaching a total of 79 clients signed year-to-date, exceeding its 2025 target of 40
DarioHealth Far Exceeds 2025 New Client Target with 79 New Accounts Signed Year-to-Date
34 new employer clients added in the past two weeks expected to contribute to H1 2026 revenue Data-driven outcomes drive employer adoption, highlighting Dario's market leadership as partner of choice,...
DarioHealth announces publication of study in JMIR on digital health platform
DarioHealth (DRIO) announced the publication of a new peer-reviewed study in the Journal of Medical Internet Research, JMIR, evaluating healthcare utilization and medical costs among Dario users compa...
DarioHealth Announces Publication of Sanofi Study in JMIR Demonstrating an Estimated $5,077 Medical Cost Savings Per Dario Digital Health Platform User Per Year
Sanofi and Symphony Health teams conducted the study demonstrating how Dario's digital, diabetes intervention platform reduces real-world healthcare burden and cost compared to usual care Representing...
DarioHealth price target raised to $11 from 60c at TD Cowen
TD Cowen raised the firm’s price target on DarioHealth (DRIO) to $11 from 60c and keeps a Hold rating on the shares. The company updated its model following Q3 results
DarioHealth price target lowered to $16 at Stifel after reverse stock split
Stifel analyst David Grossman adjusted the firm’s price target on DarioHealth (DRIO) to $16 from $1.25 and keeps a Buy rating on the shares. While “encouraged” by management’s ability to
DarioHealth Earnings Call Transcript: Q3 2025
Q3 2025 revenue declined to $5 million due to a strategic shift to high-margin recurring revenue, but gross margins and operating efficiency improved significantly. With 45 new accounts signed YTD and a robust pipeline, the company targets $12.4 million in new business for 2026 and expects to reach cash flow breakeven by late 2026 to early 2027.